Replimune Group heads into its August 18 earnings print caught between a sharp short-interest build and the most concentrated analyst upgrade cycle the stock has seen in months.
The short-side story is the most striking element of the setup. Short interest has climbed to 32.4% of the free float — and it has done so fast, surging 37% in a single week to reach 25.4 million shares. That is a meaningful jump in borrowed conviction against a stock that has already rallied 52% over the past month to close at $14.97. Yet the borrow market itself does not corroborate squeeze pressure: availability runs at 1,227% — roughly twelve shares available for every one currently borrowed — and borrowing costs have eased 25% over the past month to a near-negligible 0.66%. Short sellers are piling in, but the lending pool is loose enough that there is no structural friction forcing them out. The ORTEX short score of 55.5 reinforces this: elevated, but not extreme.
The analyst community has moved sharply in the opposite direction. JP Morgan raised its target to $20 and maintained Overweight on August 7. Wedbush upgraded to Outperform the same day, lifting its target from $12 to $19 — a notable reversal given it spent the preceding weeks at Neutral. Leerink Partners also upgraded to Outperform on August 4, with a target jump from $11 to $17. All three moves came after a cluster of April downgrades from the same firms, when FDA concerns over the IGNYTE-3 trial design rattled confidence. The Street's bull case centres on Replimune's RPx oncolytic platform and a BLA resubmission for RP1 plus nivolumab now under a fresh FDA review team. The bear case — still live — points to an interim OS readout not expected until 2027, limited near-term catalysts, and ongoing cash burn in a pre-profit biotech. The consensus sits at five buys with a mean target of $19.33, implying roughly 29% upside to the current price.
Institutional flow reinforces the bullish tilt. BlackRock added 2.7 million shares in the period ending July 31, lifting its stake to nearly 10.7% of shares outstanding. Goldman Sachs more than doubled its position over the same window, adding 2.1 million shares. The insider picture cuts the other way: the CEO, CFO, CMO, and Chief Accounting Officer all sold shares on August 10 at $12.97 — a coordinated exercise that netted just over $900,000 combined. The sales look routine in size and were executed at prices well below where the stock trades today, but their timing, just days before the print, is worth noting. Past earnings reactions have been mixed: the August 6 event saw just a 1.9% one-day move but a 28% five-day drift, while the prior two prints both saw negative one-day and five-day reactions.
Monday's report is less a test of whether Replimune's platform works and more a test of whether management can articulate a credible path through the FDA process — and whether the cash runway holds up against that timeline — in a stock where short sellers and analysts are now betting on opposite outcomes.
See the live data behind this article on ORTEX.
Open REPL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
